Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies

PLoS Comput Biol. 2017 Jan 6;13(1):e1005321. doi: 10.1371/journal.pcbi.1005321. eCollection 2017 Jan.

Abstract

Identifying optimal dosing of antibiotics has proven challenging-some antibiotics are most effective when they are administered periodically at high doses, while others work best when minimizing concentration fluctuations. Mechanistic explanations for why antibiotics differ in their optimal dosing are lacking, limiting our ability to predict optimal therapy and leading to long and costly experiments. We use mathematical models that describe both bacterial growth and intracellular antibiotic-target binding to investigate the effects of fluctuating antibiotic concentrations on individual bacterial cells and bacterial populations. We show that physicochemical parameters, e.g. the rate of drug transmembrane diffusion and the antibiotic-target complex half-life are sufficient to explain which treatment strategy is most effective. If the drug-target complex dissociates rapidly, the antibiotic must be kept constantly at a concentration that prevents bacterial replication. If antibiotics cross bacterial cell envelopes slowly to reach their target, there is a delay in the onset of action that may be reduced by increasing initial antibiotic concentration. Finally, slow drug-target dissociation and slow diffusion out of cells act to prolong antibiotic effects, thereby allowing for less frequent dosing. Our model can be used as a tool in the rational design of treatment for bacterial infections. It is easily adaptable to other biological systems, e.g. HIV, malaria and cancer, where the effects of physiological fluctuations of drug concentration are also poorly understood.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents* / administration & dosage
  • Anti-Bacterial Agents* / pharmacokinetics
  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Bacterial Infections / drug therapy*
  • Bacterial Infections / microbiology*
  • Bacterial Physiological Phenomena / drug effects
  • Computational Biology
  • Drug Resistance, Bacterial
  • Humans
  • Kinetics
  • Microbial Sensitivity Tests
  • Models, Biological*

Substances

  • Anti-Bacterial Agents

Grants and funding

This work was supported by Bill & Melinda Gates foundation (http://www.gatesfoundation.org/) grant OPP1111658 (TC and PAzW), Swiss National Science Foundation (www.snf.ch) grant PBEZP3_140163 (PAzW) and the Northern Norway Regional Health Authority/ Faculty of Health Sciences, UIT-The Arctic University of Norway (http://www.helse-nord.no/?lang=no_NO, PAzW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.